Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14019651 | 0.96 | CNR2 (0.40) | CNR2RORARORCRORBCNR1 | |
| SCHEMBL14019665 | 0.88 | TOP1 (0.38) | CNR2CNR1RXFP1 | |
| SCHEMBL14019657 | 0.84 | RXFP1 (0.34) | CNR2S1PR1SLC6A2RXFP1 | |
| SCHEMBL4030026 | 0.80 | KDM4E (0.42) | PPARAPPARGS1PR1 | |
| SCHEMBL13799088 | 0.79 | KDM4E (0.42) | PPARAPPARG | |
| SCHEMBL1132860 | 0.78 | LMNA (0.46) | GABRA1GABRB2RXFP1 | |
| Hydrochloric Acid SCHEMBL3288212 | 0.78 | KDM4E (0.41) | PPARAPPARG | |
| SCHEMBL14530146 | 0.76 | KDM4E (0.38) | PPARAPPARGPLA2G4AKAT8S1PR1 | |
| SCHEMBL14019668 | 0.76 | CNR1 (0.39) | CNR2CNR1SLC6A2 | |
| SCHEMBL14529767 | 0.76 | PPARA (0.38) | PPARAPPARGPLA2G4AKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269146-A1 | 4''-Substituted Erythromycin Derivative | MRPL21, CYP3A4, CYP51A1 | CNR2 4534/4885RORA 345/4885RORC 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.